Publications
Publications
Show Results For
-
All HBS Web
(165)
- Faculty Publications (28)
Page 1 of
28
Results
→
- Article
What Evolution Can Teach Us About Innovation
By: Noubar Afeyan and Gary P. Pisano
Many people believe that the process for achieving breakthrough innovations is chaotic, random, and unmanageable. But that view is flawed, the authors argue. Breakthroughs can be systematically generated using a process modeled on the principles that drive evolution in...
View Details
- May 2021
- Case
The SMA Foundation: Steering Therapeutic Research and Development in a Rare Disease
By: Amitabh Chandra, Spencer Lee-Rey and Caroline Marra
This case explores incentives for rare disease drug development by chronicling the role of the Spinal Muscular Atrophy (SMA) Foundation in forming strategic partnerships with the scientific research community and pharmaceutical developers to transform the trajectory...
View Details
- February 2021
- Case
Digital Manufacturing at Amgen
By: Shane Greenstein, Kyle R. Myers and Sarah Mehta
This case discusses efforts made by biotechnology (biotech) company Amgen to introduce digital technologies into its manufacturing processes. Doing so is complicated by the fact that the process for manufacturing biologics—or therapeutics made from living cells—is...
View Details
Keywords:
Digital Technologies;
Change;
Change Management;
Decision Making;
Cost vs Benefits;
Decisions;
Information;
Analytics and Data Science;
Innovation and Invention;
Innovation and Management;
Innovation Leadership;
Innovation Strategy;
Technological Innovation;
Jobs and Positions;
Knowledge;
Leadership;
Organizational Culture;
Science;
Strategy;
Information Technology;
Technology Adoption;
Biotechnology Industry;
Pharmaceutical Industry;
United States;
California;
Puerto Rico;
Rhode Island
- Article
Sustainability, Business, and Health
By: George Serafeim, Amanda M. Rischbieth and Howard K. Koh
The coronavirus disease 2019 (COVID-19) pandemic has demonstrated that response demands involvement from every sector of society. As a major example, some businesses have stepped up in ways previously unimaginable. Garment companies have repurposed production to face...
View Details
- October 2019
- Article
Adaptive Platform Trials: Definition, Design, Conduct and Reporting Considerations
By: Derek C. Angus, Brian M. Alexander, Scott Berry, Meredith Buxton, Roger Lewis, Melissa Paoloni, Steven A. R. Webb, Steven Arnold, Anna Barker, Donald A. Berry, Marc J. M. Bonten, Mary Brophy, Christopher Butler, Timothy F. Cloughesy, Lennie P. G. Derde, Laura J. Esserman, Ryan Ferguson, Louis Fiore, Sarah C. Gaffey, J. Michael Gaziano, Kathy Giusti, Herman Goossens, Stephane Heritier, Bradley Hyman, Michael Krams, Kay Larholt, Lisa M. LaVange, Philip Lavori, Andrew W. Lo, Alexander J. London, Victoria Manax, Colin McArthur, Genevieve O’Neill, Giovanni Parmigiani, Jane Perlmutter, Elizabeth A. Petzold, Craig Ritchie, Kathryn M. Rowan, Christopher W. Seymour, Nathan I. Shapiro, Diane M. Simeone, Bradley Smith, Bradley Spellberg, Ariel Dora Stern, Lorenzo Trippa, Mark Trusheim, Kert Viele, Patrick Y. Wen and Janet Woodcock
Researchers, clinicians, policymakers, and patients are increasingly interested in questions about therapeutic interventions that are difficult or costly to answer with traditional, free-standing, parallel-group randomized controlled trials (RCTs). Examples include...
View Details
- September 2019
- Case
Nimbus Therapeutics
By: Peter Barrett, Karim Lakhani and Julia Kelley
This case focuses on Nimbus Therapeutics, a biotechnology startup based in Cambridge, Massachusetts, as its leadership team tries to determine the company’s long-term strategy. The startup’s founders structured Nimbus as a limited liability company, which has given it...
View Details
- Article
Managing the Use and Dissemination of Information about Biomarkers: The Importance of Incentive Structures.
By: Ariel Dora Stern
The use of biomarkers holds great promise for the development of new therapeutics and the acceleration of clinical research. However, biomarkers must be validated—a complex and costly endeavor. Importantly, biomarker validation is meaningfully shaped by economic and...
View Details
- April 2019
- Case
Barber Cardiosystems
By: Ranjay Gulati and Paul S. Myers
Barber Cardiosystems, based in Melbourne, Australia, designs and manufactures therapeutic devices used for treatment of coronary conditions. Over four decades, it has grown to be among the top 200 medical device companies in the world. It competes against much larger...
View Details
- February 2019 (Revised May 2019)
- Case
Hot Chicken Takeover
By: William R. Kerr, Manjari Raman and Olivia Hull
By December 2018, entrepreneur Joe DeLoss’s fried chicken company, Hot Chicken Takeover, has opened three restaurants in Columbus, Ohio, using an unconventional employment model that helps people with criminal records get back on their feet. DeLoss is proud of the...
View Details
Keywords:
Fair Chance Employment;
Fair Chance Hiring;
Open Hiring;
Inclusive Hiring;
Criminal Record;
Homelessness;
Therapeutic Employment;
Corporate Culture;
Managing The Future Of Work;
Food;
Entrepreneurship;
Social Entrepreneurship;
Values and Beliefs;
Fairness;
Human Resources;
Compensation and Benefits;
Recruitment;
Employees;
Retention;
Selection and Staffing;
Innovation Strategy;
Job Offer;
Job Interviews;
Human Capital;
Leadership;
Growth Management;
Corporate Social Responsibility and Impact;
Mission and Purpose;
Social Enterprise;
Social Issues;
Poverty;
Welfare;
Food and Beverage Industry;
Ohio;
United States
- November 2018
- Case
David Hysong and SHEPHERD Therapeutics
By: Ananth Raman, John Masko and Aldo Sesia
In 2016, David Hysong, at age 27, found out he had a rare, incurable cancer. Rather than wait around to die, Hysong, a recent graduate of Harvard Divinity School, decided to launch a biotechnology company called Shepherd Therapeutics to development treatments for his...
View Details
- May 2017
- Other Article
Stepwise Distributed Open Innovation Contests for Software Development: Acceleration of Genome-Wide Association Analysis
By: Andrew Hill, Po-Ru Loh, Ragu B. Bharadwaj, Pascal Pons, Jingbo Shang, Eva C. Guinan, Karim R. Lakhani, Iain Kilty and Scott Jelinsky
BACKGROUND:
The association of differing genotypes with disease-related phenotypic traits offers great potential to both help identify new therapeutic targets and support stratification of patients who would gain the greatest benefit from specific drug classes....
View Details
- March 17, 2017
- Article
How Economics Can Shape Precision Medicines
By: Ariel Dora Stern, Brian M. Alexander and Amitabh Chandra
Many public and private efforts in coming years will focus on research in precision medicine, developing biomarkers to indicate which patients are likely to benefit from a certain treatment so that others can be spared the cost—financial and physical—of being treated...
View Details
- November 2016
- Case
Anthony Starks at InSiL Therapeutics (A)
By: Gary Pisano and Vicki Sato
When Bruce Wayne hired Anthony Starks, he thought he had hit a home run by getting the most brilliant and passionate scientist-leader in the field to be his CSO. But a few months in, Wayne and Starks begin to clash over crucial forward-looking decisions about the...
View Details
- November 2016 (Revised December 2016)
- Supplement
Anthony Starks at InSiL Therapeutics (B)
By: Vicki Sato and Gary Pisano
This case accompanies the (A) case from Anthony Starks's perspective.
View Details
- February 2016 (Revised September 2017)
- Case
Neurotrack and the Alzheimer's Puzzle
By: Richard G. Hamermesh, Liz Kind and Carin-Isabel Knoop
Elli Kaplan founded Neurotrack in 2012 with a breakthrough noninvasive cognitive diagnostics test that will detect Alzheimer's disease in its earliest pre-symptomatic stages. While the company has gained great traction in the three years since it was started, with no...
View Details
- January 2016 (Revised January 2019)
- Case
The Allergan Board Under Fire (A)
By: Lynn S. Paine, Suraj Srinivasan, John C. Coates and David Lane
In 2014, the Allergan Inc. board of directors received a surprise takeover offer from Valeant Pharmaceuticals in alliance with hedge fund activist Bill Ackman's Pershing Square Capital Management. In the unprecedented arrangement between an acquirer and a hedge fund...
View Details
Keywords:
Allergan, Inc.;
Valeant;
Ackman;
Pershing Square;
Tender Offer;
Activist Investors;
Business Models;
R＆D;
Board Of Directors;
Securities Litigation;
Acquisition Strategy;
Takeover Defenses;
Hedge Funds;
Shareholder Rights;
Proxy Contest;
Shareholder Special Meetings;
Legal Issues In Contested Takeovers;
Governing and Advisory Boards;
Mergers and Acquisitions;
Corporate Governance;
Management Teams;
Business and Shareholder Relations;
Pharmaceutical Industry
- January 2016 (Revised January 2019)
- Supplement
The Allergan Board Under Fire (B)
By: Lynn S. Paine, Suraj Srinivasan, John C. Coates and David Lane
In 2014, the Allergan Inc. board of directors received a surprise takeover offer from Valeant Pharmaceuticals in alliance with hedge fund activist Bill Ackman's Pershing Square Capital Management. In the unprecedented arrangement between an acquirer and a hedge fund...
View Details
Keywords:
Allergan, Inc.;
Valeant;
Ackman;
Pershing Square;
Tender Offer;
Activist Investors;
Business Models;
R＆D;
Board Of Directors;
Securities Litigation;
Acquisition Strategy;
Takeover Defenses;
Hedge Funds;
Shareholder Rights;
Proxy Contest;
Shareholder Special Meetings;
Legal Issues In Contested Takeovers;
Corporate Governance;
Investment Activism;
Business and Stakeholder Relations;
Business Model;
Business and Shareholder Relations;
Valuation;
Pharmaceutical Industry
- September 2014
- Case
Pfizer's Centers for Therapeutic Innovation (CTI)
By: Gary Pisano, James Weber and Kait Szydlowski
In 2010, Pfizer established four small research units in New York, Boston, San Francisco, and San Diego located close to several premier Academic Medical Centers (AMCs), or hospitals with adjoining medical schools. The goal of these units was to redesign collaboration...
View Details
Keywords:
Drug Development;
Academic Collaboration;
Research And Development;
Innovation;
Translational Research;
Management;
Operations;
Problems and Challenges;
Research;
Science;
Information Technology;
Strategy;
Biotechnology Industry;
Pharmaceutical Industry;
North and Central America;
Europe;
Asia
- September 2013
- Article
Testimonials Do Not Convert Patients from Brand to Generic Medication
By: John Beshears, James J. Choi, David Laibson, Brigitte C. Madrian and Gwendolyn Reynolds
Objectives: To assess whether the addition of a peer testimonial to an informational mailing increases conversion rates from brand name prescription medications to lower-cost therapeutic equivalents, and whether the testimonial's efficacy increases when... View Details
- November 2012 (Revised January 2013)
- Case
Companion Diagnostics: Uncertainties for Approval and Reimbursement
By: Richard G. Hamermesh, Norman C. Selby and Phillip Andrews
The FDA approvals of novel therapeutics were seen as signs in the personalized medicine community of real progress in the growth of personalized medicine. The FDA's approval of such drugs, along with companion diagnostics, suggested a shift in thinking and regulatory...
View Details